BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Heppeler A, Froidevaux S, Eberle AN, Maecke HR. Receptor targeting for tumor localisation and therapy with radiopeptides. Curr Med Chem. 2000;7:971-994. [PMID: 10911025 DOI: 10.2174/0929867003374516] [Cited by in Crossref: 177] [Cited by in F6Publishing: 152] [Article Influence: 8.0] [Reference Citation Analysis]
Number Citing Articles
1 Shi H, Cheng Z. MC1R and melanin-based molecular probes for theranostic of melanoma and beyond. Acta Pharmacol Sin 2022. [PMID: 36008707 DOI: 10.1038/s41401-022-00970-y] [Reference Citation Analysis]
2 Fesenko AA, Shutalev AD. A general and stereoselective approach to 14-membered cyclic bis-semicarbazones involving BF3-catalyzed amidoalkylation of 2-(trimethylsilyloxy)propene. Org Biomol Chem 2022;20:4569-88. [PMID: 35593300 DOI: 10.1039/d2ob00644h] [Reference Citation Analysis]
3 Klussmeier A, Aurich S, Niederstadt L, Wiedenmann B, Grötzinger C. Secretin Receptor as a Target in Gastrointestinal Cancer: Expression Analysis and Ligand Development. Biomedicines 2022;10:536. [DOI: 10.3390/biomedicines10030536] [Reference Citation Analysis]
4 O'Dorisio TM, Harris AG, O'Dorisio MS. Evolution of Neuroendocrine Tumor Therapy. Surg Oncol Clin N Am 2020;29:145-63. [PMID: 32151353 DOI: 10.1016/j.soc.2019.11.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
5 Mikulová MB, Mikuš P. Advances in Development of Radiometal Labeled Amino Acid-Based Compounds for Cancer Imaging and Diagnostics. Pharmaceuticals (Basel) 2021;14:167. [PMID: 33669938 DOI: 10.3390/ph14020167] [Cited by in Crossref: 1] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
6 Abbasi Gharibkandi N, Conlon JM, Hosseinimehr SJ. Strategies for improving stability and pharmacokinetic characteristics of radiolabeled peptides for imaging and therapy. Peptides 2020;133:170385. [PMID: 32822772 DOI: 10.1016/j.peptides.2020.170385] [Cited by in Crossref: 6] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
7 Saw PE, Song EW. Phage display screening of therapeutic peptide for cancer targeting and therapy. Protein Cell 2019;10:787-807. [PMID: 31140150 DOI: 10.1007/s13238-019-0639-7] [Cited by in Crossref: 45] [Cited by in F6Publishing: 69] [Article Influence: 15.0] [Reference Citation Analysis]
8 Pitner R, Kim J, Davis-Bergthold J, Turner C, Vassal-Stermann E, Wang H, Adams J, Carter L, Ahlgren JA, Fender P, Lieber A, Carter D, Gray SA. Structure-based Design of JOC-x, a Conjugatable Tumor Tight Junction Opener to Enhance Cancer Therapy. Sci Rep 2019;9:6169. [PMID: 30992466 DOI: 10.1038/s41598-019-42229-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 6] [Article Influence: 0.3] [Reference Citation Analysis]
9 Rezazadeh F, Sadeghzadeh N. Tumor targeting with 99m Tc radiolabeled peptides: Clinical application and recent development. Chem Biol Drug Des 2019;93:205-21. [PMID: 30299570 DOI: 10.1111/cbdd.13413] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 4.0] [Reference Citation Analysis]
10 Rezazadeh F, Sadeghzadeh N, Abedi SM, Abediankenari S. 99mTc labeled D(LPR): A novel retro-inverso peptide for VEGF receptor-1 targeted tumor imaging. Nucl Med Biol 2018;62-63:54-62. [PMID: 29885559 DOI: 10.1016/j.nucmedbio.2018.05.005] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.5] [Reference Citation Analysis]
11 Zhang H, Shen G, Zhang S, Du F, Cao Y, Jiang J, Zheng F, Ma X, Wang Z, Ren D, Ahmad R, Zhao F, Zhao J. Novel fluoropyrimidine-based chemotherapy for advanced well-differentiated neuroendocrine tumors: a clinical update. Expert Opin Pharmacother 2018;19:795-807. [PMID: 29693454 DOI: 10.1080/14656566.2018.1465928] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
12 Kumar K, Ghosh A. 18F-AlF Labeled Peptide and Protein Conjugates as Positron Emission Tomography Imaging Pharmaceuticals. Bioconjug Chem 2018;29:953-75. [PMID: 29463084 DOI: 10.1021/acs.bioconjchem.7b00817] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 5.5] [Reference Citation Analysis]
13 Hardiansyah D, Guo W, Attarwala AA, Kletting P, Mottaghy FM, Glatting G. Treatment planning in PRRT based on simulated PET data and a PBPK model: Determination of accuracy using a PET noise model. Nuklearmedizin 2018;56:23-30. [DOI: 10.3413/nukmed-0819-16-04] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
14 Shutalev AD, Fesenko AA, Yankov AN, Tafeenko VA, Chernyshev VV. 14-Membered cyclic bis-semicarbazones: Stereoselective synthesis and structural features. Journal of Molecular Structure 2017;1150:349-57. [DOI: 10.1016/j.molstruc.2017.08.096] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
15 Bodei L, Ćwikla JB, Kidd M, Modlin IM. The role of peptide receptor radionuclide therapy in advanced/metastatic thoracic neuroendocrine tumors. J Thorac Dis 2017;9:S1511-23. [PMID: 29201454 DOI: 10.21037/jtd.2017.09.82] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
16 Maupillier W, Journot G, Stoeckli-evans H, Neier R. An Efficient Synthetic Approach to Calix[ n ]furan[4- n ]pyrroles and the Calix[ n ]tetrahydrofuran[4- n ]pyrrolidines: An Efficient Synthetic Approach to Calix[ n ]furan[4- n ]pyrroles and the Calix[ n ]tetrahydrofuran[4- n ]pyrrolidines. Eur J Org Chem 2017;2017:6023-37. [DOI: 10.1002/ejoc.201701156] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
17 Hardiansyah D, Attarwala AA, Kletting P, Mottaghy FM, Glatting G. Prediction of time-integrated activity coefficients in PRRT using simulated dynamic PET and a pharmacokinetic model. Phys Med 2017;42:298-304. [PMID: 28739143 DOI: 10.1016/j.ejmp.2017.06.024] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.4] [Reference Citation Analysis]
18 De K, Banerjee I, Sinha S, Ganguly S. Synthesis and exploration of novel radiolabeled bombesin peptides for targeting receptor positive tumor. Peptides 2017;89:17-34. [PMID: 28088445 DOI: 10.1016/j.peptides.2017.01.002] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
19 Bodei L, Kwekkeboom DJ, Kidd M, Modlin IM, Krenning EP. Radiolabeled Somatostatin Analogue Therapy Of Gastroenteropancreatic Cancer. Semin Nucl Med. 2016;46:225-238. [PMID: 27067503 DOI: 10.1053/j.semnuclmed.2015.12.003] [Cited by in Crossref: 57] [Cited by in F6Publishing: 57] [Article Influence: 9.5] [Reference Citation Analysis]
20 Fesenko AA, Yankov AN, Shutalev AD. An efficient and stereoselective approach to 14-membered hexaaza macrocycles using novel semicarbazone-based amidoalkylation reagents. Tetrahedron Letters 2016;57:5784-7. [DOI: 10.1016/j.tetlet.2016.11.041] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
21 Reubi JC. Peptide Receptors as Molecular Targets for Cancer Diagnosis and Therapy. Endocrine Reviews 2003;24:389-427. [DOI: 10.1210/er.2002-0007] [Cited by in Crossref: 757] [Cited by in F6Publishing: 704] [Article Influence: 126.2] [Reference Citation Analysis]
22 Petrik M, Zhai C, Haas H, Decristoforo C. Siderophores for molecular imaging applications. Clin Transl Imaging 2017;5:15-27. [PMID: 28138436 DOI: 10.1007/s40336-016-0211-x] [Cited by in Crossref: 61] [Cited by in F6Publishing: 66] [Article Influence: 10.2] [Reference Citation Analysis]
23 Narayanan S, Kunz PL. Role of Somatostatin Analogues in the Treatment of Neuroendocrine Tumors. Hematol Oncol Clin North Am 2016;30:163-77. [PMID: 26614375 DOI: 10.1016/j.hoc.2015.09.008] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 2.8] [Reference Citation Analysis]
24 Holland JP, Ferdani R, Anderson CJ, Lewis JS. Copper-64 Radiopharmaceuticals for Oncologic Imaging. PET Clin 2009;4:49-67. [PMID: 27156895 DOI: 10.1016/j.cpet.2009.04.013] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
25 Kim EJ, Kim BS, Choi DB, Chi SG, Choi TH. Enhanced tumor retention of radioiodinated anti-epidermal growth factor receptor antibody using novel bifunctional iodination linker for radioimmunotherapy. Oncol Rep 2016;35:3159-68. [PMID: 27035553 DOI: 10.3892/or.2016.4706] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
26 Kunz PL. Carcinoid and neuroendocrine tumors: building on success. J Clin Oncol. 2015;33:1855-1863. [PMID: 25918282 DOI: 10.1200/jco.2014.60.2532] [Cited by in Crossref: 88] [Cited by in F6Publishing: 88] [Article Influence: 12.6] [Reference Citation Analysis]
27 Narayanan S, Kunz PL. Beyond biologics: is there a role for systemic cytotoxic chemotherapy in neuroendocrine tumors? International Journal of Endocrine Oncology 2015;2:13-20. [DOI: 10.2217/ije.14.37] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
28 Dash A, Chakraborty S, Pillai MR, Knapp FF. Peptide receptor radionuclide therapy: an overview. Cancer Biother Radiopharm. 2015;30:47-71. [PMID: 25710506 DOI: 10.1089/cbr.2014.1741] [Cited by in Crossref: 63] [Cited by in F6Publishing: 65] [Article Influence: 9.0] [Reference Citation Analysis]
29 Zhu W, Zhang K, Chen Y. Block copolymer micelles as carriers of transition metal ions Y(III) and Cu(II) and gelation thereof. Polymer 2014;55:6232-8. [DOI: 10.1016/j.polymer.2014.10.009] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
30 Sista P, Ghosh K, Martinez JS, Rocha RC. Metallo-Biopolymers: Conjugation Strategies and Applications. Polymer Reviews 2014;54:627-76. [DOI: 10.1080/15583724.2014.913063] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
31 Maina T, Cescato R, Waser B, Tatsi A, Kaloudi A, Krenning EP, de Jong M, Nock BA, Reubi JC. [ 111 In-DOTA]LTT-SS28, a First Pansomatostatin Radioligand for in Vivo Targeting of Somatostatin Receptor-Positive Tumors. J Med Chem 2014;57:6564-71. [DOI: 10.1021/jm500581d] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
32 de Herder WW. GEP-NETS update: functional localisation and scintigraphy in neuroendocrine tumours of the gastrointestinal tract and pancreas (GEP-NETs). Eur J Endocrinol 2014;170:R173-83. [PMID: 24723670 DOI: 10.1530/EJE-14-0077] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 2.0] [Reference Citation Analysis]
33 Baldelli R, Barnabei A, Rizza L, Isidori AM, Rota F, Di Giacinto P, Paoloni A, Torino F, Corsello SM, Lenzi A, Appetecchia M. Somatostatin analogs therapy in gastroenteropancreatic neuroendocrine tumors: current aspects and new perspectives. Front Endocrinol (Lausanne). 2014;5:7. [PMID: 24570674 DOI: 10.3389/fendo.2014.00007] [Cited by in Crossref: 35] [Cited by in F6Publishing: 37] [Article Influence: 4.4] [Reference Citation Analysis]
34 Stasiuk GJ, Long NJ. The ubiquitous DOTA and its derivatives: the impact of 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid on biomedical imaging. Chem Commun (Camb) 2013;49:2732-46. [PMID: 23392443 DOI: 10.1039/c3cc38507h] [Cited by in Crossref: 142] [Cited by in F6Publishing: 136] [Article Influence: 15.8] [Reference Citation Analysis]
35 Erfani M, Shafiei M, Mazidi M, Goudarzi M. Preparation and Biological Evaluation of [ 99m Tc/EDDA/Tricine/HYNIC 0 , BzThi 3 ]-Octreotide for Somatostatin Receptor-Positive Tumor Imaging. Cancer Biotherapy and Radiopharmaceuticals 2013;28:240-7. [DOI: 10.1089/cbr.2012.1270] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
36 Jamous M, Haberkorn U, Mier W. Synthesis of peptide radiopharmaceuticals for the therapy and diagnosis of tumor diseases. Molecules 2013;18:3379-409. [PMID: 23493103 DOI: 10.3390/molecules18033379] [Cited by in Crossref: 51] [Cited by in F6Publishing: 48] [Article Influence: 5.7] [Reference Citation Analysis]
37 Lu X, Yan P, Wang RF, Liu M, Yu MM, Zhang CL. Use of Radioiodinated Peptide Arg-Arg-Leu Targeted to Neovasculari- zation as well as Tumor Cells in Molecular Tumor Imaging. Chin J Cancer Res 2012;24:52-9. [PMID: 23359762 DOI: 10.1007/s11670-012-0052-8] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
38 Jamous M, Haberkorn U, Mier W. DOTA-tris(OPp ester) as a bifunctional prochelator for the preparation of DOTA–peptide conjugates. Tetrahedron Letters 2012;53:6810-4. [DOI: 10.1016/j.tetlet.2012.10.007] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
39 Sulieman S, Can D, Mertens J, N’dongo HWP, Liu Y, Schmutz P, Bauwens M, Spingler B, Alberto R. Cyclopentadienyl-Based Amino Acids (Cp-aa) As Phenylalanine Analogues for Tumor Targeting: Syntheses and Biological Properties of [(Cp-aa)M(CO) 3 ](M = Mn, Re, 99m Tc). Organometallics 2012;31:6880-6. [DOI: 10.1021/om300695k] [Cited by in Crossref: 24] [Cited by in F6Publishing: 15] [Article Influence: 2.4] [Reference Citation Analysis]
40 Ha YS, Lee HY, An GI, Kim J, Kwak W, Lee EJ, Lee SM, Lee BH, Kim IS, Belay T, Lee W, Ahn BC, Lee J, Yoo J. Synthesis and evaluation of a radioiodinated bladder cancer specific peptide. Bioorg Med Chem 2012;20:4330-5. [PMID: 22705190 DOI: 10.1016/j.bmc.2012.05.049] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
41 Notni J. Mit Gallium-68 in ein neues Zeitalter? Nachr Chem 2012;60:645-9. [DOI: 10.1002/nadc.201290233] [Cited by in Crossref: 17] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
42 Baum RP, Kulkarni HR, Carreras C. Peptides and Receptors in Image-Guided Therapy: Theranostics for Neuroendocrine Neoplasms. Seminars in Nuclear Medicine 2012;42:190-207. [DOI: 10.1053/j.semnuclmed.2012.01.002] [Cited by in Crossref: 89] [Cited by in F6Publishing: 71] [Article Influence: 8.9] [Reference Citation Analysis]
43 Schmitt JS, Wild D, Ginj M, Reubi JC, Waser B, de Jong M, Bernard BF, Krenning EP, Mäcke HR. DOTA-NOC, A high affinity ligand of the somatostatin receptor subtypes 2, 3 and 5 for radiotherapy. J Label Compd Radiopharm 2001;44:S697-9. [DOI: 10.1002/jlcr.25804401246] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
44 Savelli G, Bertagna F, Franco F, Dognini L, Bosio G, Migliorati E, Rodella C, Biasiotto G, Bettinsoli G, Minari C, Zaniboni A, Ferrari C, Tomassetti P, Ferrari V, Giubbini R. Final results of a phase 2A study for the treatment of metastatic neuroendocrine tumors with a fixed activity of 90Y-DOTA-D-Phe1-Tyr3 octreotide. Cancer 2012;118:2915-24. [DOI: 10.1002/cncr.26616] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.1] [Reference Citation Analysis]
45 Cona MM, Wang H, Li J, Feng Y, Chen F, de Witte P, Verbruggen A, Ni Y. Continuing pursuit for ideal systemic anticancer radiotherapeutics. Invest New Drugs 2012;30:2050-65. [PMID: 22006160 DOI: 10.1007/s10637-011-9758-6] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
46 Galbán CJ, Galbán S, Van Dort ME, Luker GD, Bhojani MS, Rehemtulla A, Ross BD. Applications of molecular imaging. Prog Mol Biol Transl Sci. 2010;95:237-298. [PMID: 21075334 DOI: 10.1016/B978-0-12-385071-3.00009-5] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.1] [Reference Citation Analysis]
47 Culler MD, Oberg K, Arnold R, Krenning EP, Sevilla I, Díaz JA. Somatostatin analogs for the treatment of neuroendocrine tumors. Cancer Metastasis Rev. 2011;30 Suppl 1:9-17. [PMID: 21369878 DOI: 10.1007/s10555-011-9293-0] [Cited by in Crossref: 31] [Cited by in F6Publishing: 33] [Article Influence: 2.8] [Reference Citation Analysis]
48 Kniess T, Kuchar M, Pietzsch J. Automated radiosynthesis of the thiol-reactive labeling agent N-[6-(4-[18F]fluorobenzylidene)aminooxyhexyl]maleimide ([18F]FBAM). Appl Radiat Isot 2011;69:1226-30. [PMID: 21507666 DOI: 10.1016/j.apradiso.2011.03.043] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 1.4] [Reference Citation Analysis]
49 Hanin FX, Pauwels S, Bol A, Melis M, Breeman W, de Jong M, Jamar F. Effect of interferon-alpha treatment on [68Ga-DOTA,Tyr3,Thre8]octreotide uptake in CA20948 tumors: a small-animal PET study. J Nucl Med 2011;52:580-5. [PMID: 21421708 DOI: 10.2967/jnumed.110.084152] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
50 Zhou Y, Chakraborty S, Liu S. Radiolabeled Cyclic RGD Peptides as Radiotracers for Imaging Tumors and Thrombosis by SPECT. Theranostics 2011;1:58-82. [PMID: 21547153 DOI: 10.7150/thno/v01p0058] [Cited by in Crossref: 89] [Cited by in F6Publishing: 84] [Article Influence: 8.1] [Reference Citation Analysis]
51 Lattuada L, Barge A, Cravotto G, Giovenzana GB, Tei L. The synthesis and application of polyamino polycarboxylic bifunctional chelating agents. Chem Soc Rev 2011;40:3019. [DOI: 10.1039/c0cs00199f] [Cited by in Crossref: 125] [Cited by in F6Publishing: 116] [Article Influence: 11.4] [Reference Citation Analysis]
52 McBride WJ, D'Souza CA, Sharkey RM, Karacay H, Rossi EA, Chang CH, Goldenberg DM. Improved 18F labeling of peptides with a fluoride-aluminum-chelate complex. Bioconjug Chem 2010;21:1331-40. [PMID: 20540570 DOI: 10.1021/bc100137x] [Cited by in Crossref: 147] [Cited by in F6Publishing: 147] [Article Influence: 12.3] [Reference Citation Analysis]
53 Müssig K, Bares R, Erckenbrecht JF, Horger M. Multimodal imaging in functional endocrine pancreatic tumors. Expert Rev Endocrinol Metab 2010;5:855-66. [PMID: 30780827 DOI: 10.1586/eem.10.57] [Reference Citation Analysis]
54 Mansi R, Wang X, Forrer F, Waser B, Cescato R, Graham K, Borkowski S, Reubi JC, Maecke HR. Development of a potent DOTA-conjugated bombesin antagonist for targeting GRPr-positive tumours. Eur J Nucl Med Mol Imaging 2011;38:97-107. [DOI: 10.1007/s00259-010-1596-9] [Cited by in Crossref: 113] [Cited by in F6Publishing: 111] [Article Influence: 9.4] [Reference Citation Analysis]
55 D'Andrea LD, Romanelli A, Di Stasi R, Pedone C. Bioinorganic aspects of angiogenesis. Dalton Trans 2010;39:7625-36. [PMID: 20535417 DOI: 10.1039/c002439b] [Cited by in Crossref: 37] [Cited by in F6Publishing: 36] [Article Influence: 3.1] [Reference Citation Analysis]
56 Huang WQ, Wang JG, Chen L, Wei HJ, Chen H. SR140333 counteracts NK-1 mediated cell proliferation in human breast cancer cell line T47D. J Exp Clin Cancer Res. 2010;29:55. [PMID: 20497542 DOI: 10.1186/1756-9966-29-55] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.0] [Reference Citation Analysis]
57 Brillouet S, Dorbes S, Courbon F, Picard C, Delord JP, Benoist E, Poirot M, Mestre-Voegtlé B, Silvente-Poirot S. Development of a new radioligand for cholecystokinin receptor subtype 2 scintigraphy: from molecular modeling to in vivo evaluation. Bioorg Med Chem 2010;18:5400-12. [PMID: 20542702 DOI: 10.1016/j.bmc.2010.05.031] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 0.9] [Reference Citation Analysis]
58 Liu S. Radiolabeled cyclic RGD peptides as integrin alpha(v)beta(3)-targeted radiotracers: maximizing binding affinity via bivalency. Bioconjug Chem 2009;20:2199-213. [PMID: 19719118 DOI: 10.1021/bc900167c] [Cited by in Crossref: 235] [Cited by in F6Publishing: 246] [Article Influence: 19.6] [Reference Citation Analysis]
59 Purgel M, Baranyai Z, de Blas A, Rodríguez-blas T, Bányai I, Platas-iglesias C, Tóth I. An NMR and DFT Investigation on the Conformational Properties of Lanthanide(III) 1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetate Analogues Containing Methylenephosphonate Pendant Arms. Inorg Chem 2010;49:4370-82. [DOI: 10.1021/ic100177n] [Cited by in Crossref: 48] [Cited by in F6Publishing: 44] [Article Influence: 4.0] [Reference Citation Analysis]
60 Appetecchia M, Baldelli R. Somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine tumours, current aspects and new perspectives. J Exp Clin Cancer Res. 2010;29:19. [PMID: 20196864 DOI: 10.1186/1756-9966-29-19] [Cited by in Crossref: 82] [Cited by in F6Publishing: 83] [Article Influence: 6.8] [Reference Citation Analysis]
61 Dorbes S, Mestre-voegtlé B, Coulais Y, Picard C, Silvente-poirot S, Poirot M, Benoist E. Synthesis, characterization and in vitro evaluation of new oxorhenium- and oxotechnetium-CCK4 derivatives as molecular imaging agents for CCK2-receptor targeting. European Journal of Medicinal Chemistry 2010;45:423-9. [DOI: 10.1016/j.ejmech.2009.09.043] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
62 Ortner A, Wernig K, Kaisler R, Edetsberger M, Hajos F, Köhler G, Mosgoeller W, Zimmer A. VPAC receptor mediated tumor cell targeting by protamine based nanoparticles. Journal of Drug Targeting 2010;18:457-67. [DOI: 10.3109/10611860903508796] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 1.3] [Reference Citation Analysis]
63 Monfregola L, Saviano M, De Luca S. Synthesis and Characterization of a Selective Alpha(v)Beta(3) Receptor Cyclic Peptide Antagonist Functionalized with a Chelating Group for Metal Labelling. Int J Pept Res Ther 2010;16:1-5. [DOI: 10.1007/s10989-009-9195-y] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
64 Hanin FX, Pauwels S, Bol A, Breeman W, de Jong M, Jamar F. Tumor uptake of 68Ga-DOTA-Tyr3-octreotate: animal PET studies of tumor flow and acute somatostatin receptor modulation in the CA20948 rat model. Nucl Med Biol 2010;37:157-65. [PMID: 20152715 DOI: 10.1016/j.nucmedbio.2009.09.006] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.5] [Reference Citation Analysis]
65 Storch D, Schmitt JS, Waldherr C, Waser B, Reubi J, Maecke HR. Preclinical evaluation of somatostatin analogs bearing two macrocyclic chelators for high specific activity labeling with radiometals. Radiochimica Acta 2007;95:359-69. [DOI: 10.1524/ract.2007.95.6.359] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
66 Tolmachev V, Carlsson J, Lundqvist H. A limiting factor for the progress of radionuclide-based cancer diagnostics and therapy--availability of suitable radionuclides. Acta Oncol 2004;43:264-75. [PMID: 15244250 DOI: 10.1080/02841860410028943] [Cited by in Crossref: 20] [Cited by in F6Publishing: 12] [Article Influence: 1.5] [Reference Citation Analysis]
67 Yang J, Guo H, Gallazzi F, Berwick M, Padilla RS, Miao Y. Evaluation of a novel Arg-Gly-Asp-conjugated α-melanocyte stimulating hormone hybrid peptide for potential melanoma therapy. Bioconjug Chem 2009;20:1634-42. [PMID: 19552406 DOI: 10.1021/bc9001954] [Cited by in Crossref: 33] [Cited by in F6Publishing: 30] [Article Influence: 2.5] [Reference Citation Analysis]
68 Emonds KM, Swinnen JV, Mortelmans L, Mottaghy FM. Molecular imaging of prostate cancer. Methods 2009;48:193-9. [PMID: 19362147 DOI: 10.1016/j.ymeth.2009.03.021] [Cited by in Crossref: 34] [Cited by in F6Publishing: 34] [Article Influence: 2.6] [Reference Citation Analysis]
69 Iovkova L, Wängler B, Schirrmacher E, Schirrmacher R, Quandt G, Boening G, Schürmann M, Jurkschat K. para-Functionalized aryl-di-tert-butylfluorosilanes as potential labeling synthons for (18)F radiopharmaceuticals. Chemistry 2009;15:2140-7. [PMID: 19156812 DOI: 10.1002/chem.200802266] [Cited by in Crossref: 48] [Cited by in F6Publishing: 46] [Article Influence: 3.7] [Reference Citation Analysis]
70 Eberle AN, Mild G. Receptor-mediated tumor targeting with radiopeptides: Part 1. General principles and methods. Journal of Receptors and Signal Transduction 2009;29:1-37. [DOI: 10.1080/10799890902732823] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 1.5] [Reference Citation Analysis]
71 Barge A, Cappelletti E, Cravotto G, Ferrigato A, Lattuada L, Marinoni F, Tei L. Synthesis of functionalised HP-DO3A chelating agents for conjugation to biomolecules. Org Biomol Chem 2009;7:3810. [DOI: 10.1039/b905369g] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
72 Wang XL, Xu R, Lu ZR. A peptide-targeted delivery system with pH-sensitive amphiphilic cell membrane disruption for efficient receptor-mediated siRNA delivery. J Control Release 2009;134:207-13. [PMID: 19135104 DOI: 10.1016/j.jconrel.2008.11.010] [Cited by in Crossref: 55] [Cited by in F6Publishing: 55] [Article Influence: 3.9] [Reference Citation Analysis]
73 Schweinsberg C, Maes V, Brans L, Bläuenstein P, Tourwé DA, Schubiger PA, Schibli R, Garayoa EG. Novel Glycated [ 99m Tc(CO) 3 ]-Labeled Bombesin Analogues for Improved Targeting of Gastrin-Releasing Peptide Receptor-Positive Tumors. Bioconjugate Chem 2008;19:2432-9. [DOI: 10.1021/bc800319g] [Cited by in Crossref: 57] [Cited by in F6Publishing: 47] [Article Influence: 4.1] [Reference Citation Analysis]
74 García Garayoa E, Schweinsberg C, Maes V, Brans L, Bläuenstein P, Tourwé DA, Schibli R, Schubiger PA. Influence of the Molecular Charge on the Biodistribution of Bombesin Analogues Labeled with the [ 99m Tc(CO) 3 ]-Core. Bioconjugate Chem 2008;19:2409-16. [DOI: 10.1021/bc800262m] [Cited by in Crossref: 72] [Cited by in F6Publishing: 69] [Article Influence: 5.1] [Reference Citation Analysis]
75 Brans L, Maes V, García-Garayoa E, Schweinsberg C, Daepp S, Bläuenstein P, Schubiger PA, Schibli R, Tourwé DA. Glycation methods for bombesin analogs containing the (NalphaHis)Ac chelator for 99mTc(CO)3 radiolabeling. Chem Biol Drug Des 2008;72:496-506. [PMID: 19016795 DOI: 10.1111/j.1747-0285.2008.00727.x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
76 Faintuch BL, Teodoro R, Duatti A, Muramoto E, Faintuch S, Smith CJ. Radiolabeled bombesin analogs for prostate cancer diagnosis: preclinical studies. Nucl Med Biol 2008;35:401-11. [PMID: 18482677 DOI: 10.1016/j.nucmedbio.2008.02.005] [Cited by in Crossref: 54] [Cited by in F6Publishing: 58] [Article Influence: 3.9] [Reference Citation Analysis]
77 Liu S. Bifunctional coupling agents for radiolabeling of biomolecules and target-specific delivery of metallic radionuclides. Adv Drug Deliv Rev 2008;60:1347-70. [PMID: 18538888 DOI: 10.1016/j.addr.2008.04.006] [Cited by in Crossref: 288] [Cited by in F6Publishing: 255] [Article Influence: 20.6] [Reference Citation Analysis]
78 D'andrea LD, Testa I, Panico M, Di Stasi R, Caracò C, Tarallo L, Arra C, Barbieri A, Romanelli A, Aloj L. In vivo and in vitro characterization of CCK8 bearing a histidine-based chelator labeled with 99mTc-tricarbonyl. Biopolymers 2008;90:707-12. [DOI: 10.1002/bip.21041] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 0.9] [Reference Citation Analysis]
79 Zwanziger D, Khan IU, Neundorf I, Sieger S, Lehmann L, Friebe M, Dinkelborg L, Beck-sickinger AG. Novel Chemically Modified Analogues of Neuropeptide Y for Tumor Targeting. Bioconjugate Chem 2008;19:1430-8. [DOI: 10.1021/bc7004297] [Cited by in Crossref: 45] [Cited by in F6Publishing: 40] [Article Influence: 3.2] [Reference Citation Analysis]
80 Flavell RR, Kothari P, Bar-Dagan M, Synan M, Vallabhajosula S, Friedman JM, Muir TW, Ceccarini G. Site-specific (18)F-labeling of the protein hormone leptin using a general two-step ligation procedure. J Am Chem Soc 2008;130:9106-12. [PMID: 18570424 DOI: 10.1021/ja801666z] [Cited by in Crossref: 63] [Cited by in F6Publishing: 58] [Article Influence: 4.5] [Reference Citation Analysis]
81 Abiraj K, Jaccard H, Kretzschmar M, Helm L, Maecke HR. Novel DOTA-based prochelator for divalent peptide vectorization: synthesis of dimeric bombesin analogues for multimodality tumor imaging and therapy. Chem Commun (Camb) 2008;:3248-50. [PMID: 18622433 DOI: 10.1039/b805281f] [Cited by in Crossref: 31] [Cited by in F6Publishing: 30] [Article Influence: 2.2] [Reference Citation Analysis]
82 Cescato R, Erchegyi J, Waser B, Piccand V, Maecke HR, Rivier JE, Reubi JC. Design and in vitro characterization of highly sst2-selective somatostatin antagonists suitable for radiotargeting. J Med Chem 2008;51:4030-7. [PMID: 18543899 DOI: 10.1021/jm701618q] [Cited by in Crossref: 77] [Cited by in F6Publishing: 71] [Article Influence: 5.5] [Reference Citation Analysis]
83 Tietze LF, Panknin O, Krewer B, Major F, Schuberth I. Synthesis and biological evaluation of a novel pentagastrin-toxin conjugate designed for a targeted prodrug mono-therapy of cancer. Int J Mol Sci 2008;9:821-37. [PMID: 19325786 DOI: 10.3390/ijms9050821] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
84 Haddad F, Ferrer L, Guertin A, Carlier T, Michel N, Barbet J, Chatal JF. ARRONAX, a high-energy and high-intensity cyclotron for nuclear medicine. Eur J Nucl Med Mol Imaging 2008;35:1377-87. [PMID: 18465127 DOI: 10.1007/s00259-008-0802-5] [Cited by in Crossref: 62] [Cited by in F6Publishing: 54] [Article Influence: 4.4] [Reference Citation Analysis]
85 Miao Y, Quinn TP. Peptide-targeted radionuclide therapy for melanoma. Crit Rev Oncol Hematol 2008;67:213-28. [PMID: 18387816 DOI: 10.1016/j.critrevonc.2008.02.006] [Cited by in Crossref: 48] [Cited by in F6Publishing: 46] [Article Influence: 3.4] [Reference Citation Analysis]
86 Tietze L, Panknin O, Major F, Krewer B. Synthesis of a Novel Pentagastrin-Drug Conjugate for a Targeted Tumor Therapy. Chem Eur J 2008;14:2811-8. [DOI: 10.1002/chem.200701521] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
87 Van Dort ME, Rehemtulla A, Ross BD. PET and SPECT Imaging of Tumor Biology: New Approaches towards Oncology Drug Discovery and Development. Curr Comput Aided Drug Des 2008;4:46-53. [PMID: 19809593 DOI: 10.2174/157340908783769265] [Cited by in Crossref: 31] [Cited by in F6Publishing: 26] [Article Influence: 2.2] [Reference Citation Analysis]
88 De León-rodríguez LM, Kovacs Z. The Synthesis and Chelation Chemistry of DOTA−Peptide Conjugates. Bioconjugate Chem 2008;19:391-402. [DOI: 10.1021/bc700328s] [Cited by in Crossref: 194] [Cited by in F6Publishing: 186] [Article Influence: 12.9] [Reference Citation Analysis]
89 Pantaleo MA, Nannini M, Maleddu A, Fanti S, Ambrosini V, Nanni C, Boschi S, Biasco G. Conventional and novel PET tracers for imaging in oncology in the era of molecular therapy. Cancer Treat Rev 2008;34:103-21. [PMID: 18055120 DOI: 10.1016/j.ctrv.2007.10.001] [Cited by in Crossref: 43] [Cited by in F6Publishing: 34] [Article Influence: 2.9] [Reference Citation Analysis]
90 Acar Ç, Teksöz S, Ünak P, Müftüler FZB, Medine EI. Somatostatin with 99m Tc and Biodistribution Studies in Rats. Cancer Biotherapy and Radiopharmaceuticals 2007;22:748-54. [DOI: 10.1089/cbr.2007.0340] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
91 Miao Y, Shelton T, Quinn TP. Therapeutic efficacy of a 177Lu-labeled DOTA conjugated alpha-melanocyte-stimulating hormone peptide in a murine melanoma-bearing mouse model. Cancer Biother Radiopharm 2007;22:333-41. [PMID: 17651039 DOI: 10.1089/cbr.2007.376.A] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 1.8] [Reference Citation Analysis]
92 Grozinsky-Glasberg S, Grossman AB, Korbonits M. The role of somatostatin analogues in the treatment of neuroendocrine tumours. Mol Cell Endocrinol. 2008;286:238-250. [PMID: 18037561 DOI: 10.1016/j.mce.2007.10.006] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 1.9] [Reference Citation Analysis]
93 Orlova A, Feldwisch J, Abrahmsén L, Tolmachev V. Update: Affibody Molecules for Molecular Imaging and Therapy for Cancer. Cancer Biotherapy and Radiopharmaceuticals 2007;22:573-84. [DOI: 10.1089/cbr.2006.004-u] [Cited by in Crossref: 45] [Cited by in F6Publishing: 45] [Article Influence: 3.0] [Reference Citation Analysis]
94 Knör S, Sato S, Huber T, Morgenstern A, Bruchertseifer F, Schmitt M, Kessler H, Senekowitsch-Schmidtke R, Magdolen V, Seidl C. Development and evaluation of peptidic ligands targeting tumour-associated urokinase plasminogen activator receptor (uPAR) for use in alpha-emitter therapy for disseminated ovarian cancer. Eur J Nucl Med Mol Imaging 2008;35:53-64. [PMID: 17891393 DOI: 10.1007/s00259-007-0582-3] [Cited by in Crossref: 29] [Cited by in F6Publishing: 33] [Article Influence: 1.9] [Reference Citation Analysis]
95 Okarvi SM. Peptide-based radiopharmaceuticals and cytotoxic conjugates: potential tools against cancer. Cancer Treat Rev. 2008;34:13-26. [PMID: 17870245 DOI: 10.1016/j.ctrv.2007.07.017] [Cited by in Crossref: 94] [Cited by in F6Publishing: 85] [Article Influence: 6.3] [Reference Citation Analysis]
96 Knör S, Modlinger A, Poethko T, Schottelius M, Wester HJ, Kessler H. Synthesis of novel 1,4,7,10-tetraazacyclodecane-1,4,7,10-tetraacetic acid (DOTA) derivatives for chemoselective attachment to unprotected polyfunctionalized compounds. Chemistry 2007;13:6082-90. [PMID: 17503419 DOI: 10.1002/chem.200700231] [Cited by in Crossref: 57] [Cited by in F6Publishing: 53] [Article Influence: 3.8] [Reference Citation Analysis]
97 Cyr JE, Pearson DA, Nelson CA, Lyons BA, Zheng Y, Bartis J, He J, Cantorias MV, Howell RC, Francesconi LC. Isolation, characterization, and biological evaluation of syn and anti diastereomers of [(99m)Tc]technetium depreotide: a somatostatin receptor binding tumor imaging agent. J Med Chem 2007;50:4295-303. [PMID: 17691760 DOI: 10.1021/jm060887v] [Cited by in Crossref: 19] [Cited by in F6Publishing: 13] [Article Influence: 1.3] [Reference Citation Analysis]
98 Laznicek M, Laznickova A, Syrovatko M. DOTA-Tyr3-octreotate radiolabeled with 111In: Stability and the effect of receptor-specific binding on distribution. J Radioanal Nucl Chem 2007;273:587-91. [DOI: 10.1007/s10967-007-0915-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
99 Tolmachev V, Orlova A, Nilsson FY, Feldwisch J, Wennborg A, Abrahmsén L. Affibody molecules: potential for in vivo imaging of molecular targets for cancer therapy. Expert Opin Biol Ther 2007;7:555-68. [PMID: 17373906 DOI: 10.1517/14712598.7.4.555] [Cited by in Crossref: 89] [Cited by in F6Publishing: 87] [Article Influence: 5.9] [Reference Citation Analysis]
100 Antunes P, Delgado R, Drew MG, Félix V, Maecke H. Copper complexes of new benzodioxotetraaza macrocycles with potential applications in nuclear medicine. Inorg Chem 2007;46:3144-53. [PMID: 17378553 DOI: 10.1021/ic062172o] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 1.3] [Reference Citation Analysis]
101 Sosabowski JK, Lee M, Dekker BA, Simmons BP, Singh S, Beresford H, Hagan SA, McKenzie AJ, Mather SJ, Watson SA. Formulation development and manufacturing of a gastrin/CCK-2 receptor targeting peptide as an intermediate drug product for a clinical imaging study. Eur J Pharm Sci 2007;31:102-11. [PMID: 17387005 DOI: 10.1016/j.ejps.2007.02.007] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 0.7] [Reference Citation Analysis]
102 Ertay T, Ünak P, Biber F, Tascı C, Zihnioğlu F, Durak H. Scintigraphic imaging with a peptide glucuronide in rabbits: 99mTc- exorphin C glucuronide. Applied Radiation and Isotopes 2007;65:170-5. [DOI: 10.1016/j.apradiso.2006.03.017] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
103 Zhang H, Schuhmacher J, Waser B, Wild D, Eisenhut M, Reubi JC, Maecke HR. DOTA-PESIN, a DOTA-conjugated bombesin derivative designed for the imaging and targeted radionuclide treatment of bombesin receptor-positive tumours. Eur J Nucl Med Mol Imaging 2007;34:1198-208. [DOI: 10.1007/s00259-006-0347-4] [Cited by in Crossref: 96] [Cited by in F6Publishing: 88] [Article Influence: 6.4] [Reference Citation Analysis]
104 García Garayoa E, Rüegg D, Bläuenstein P, Zwimpfer M, Khan IU, Maes V, Blanc A, Beck-sickinger AG, Tourwé DA, Schubiger PA. Chemical and biological characterization of new Re(CO)3/[99mTc](CO)3 bombesin analogues. Nuclear Medicine and Biology 2007;34:17-28. [DOI: 10.1016/j.nucmedbio.2006.10.004] [Cited by in Crossref: 72] [Cited by in F6Publishing: 64] [Article Influence: 4.8] [Reference Citation Analysis]
105 Delgado R, Félix V, Lima LMP, Price DW. Metal complexes of cyclen and cyclam derivatives useful for medical applications: a discussion based on thermodynamic stability constants and structural data. Dalton Trans 2007. [DOI: 10.1039/b704360k] [Cited by in Crossref: 133] [Cited by in F6Publishing: 132] [Article Influence: 8.9] [Reference Citation Analysis]
106 Decristoforo C, Faintuch-linkowski B, Rey A, von Guggenberg E, Rupprich M, Hernandez-gonzales I, Rodrigo T, Haubner R. [99mTc]HYNIC-RGD for imaging integrin αvβ3 expression. Nuclear Medicine and Biology 2006;33:945-52. [DOI: 10.1016/j.nucmedbio.2006.09.001] [Cited by in Crossref: 81] [Cited by in F6Publishing: 78] [Article Influence: 5.1] [Reference Citation Analysis]
107 Ginj M, Zhang H, Waser B, Cescato R, Wild D, Wang X, Erchegyi J, Rivier J, Mäcke HR, Reubi JC. Radiolabeled somatostatin receptor antagonists are preferable to agonists for in vivo peptide receptor targeting of tumors. Proc Natl Acad Sci USA. 2006;103:16436-16441. [PMID: 17056720 DOI: 10.1073/pnas.0607761103] [Cited by in Crossref: 311] [Cited by in F6Publishing: 281] [Article Influence: 19.4] [Reference Citation Analysis]
108 Lattuada L, Gabellini M. Straightforward Synthesis of a Novel Maleimide‐DTPA Bifunctional Chelating Agent. Synthetic Communications 2005;35:2409-13. [DOI: 10.1080/00397910500189569] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
109 Tzanopoulou S, Pirmettis IC, Patsis G, Paravatou-petsotas M, Livaniou E, Papadopoulos M, Pelecanou M. Synthesis, Characterization, and Biological Evaluation of M(I)(CO) 3 (NNO) Complexes (M = Re, 99m Tc) Conjugated to 2-(4-Aminophenyl)benzothiazole as Potential Breast Cancer Radiopharmaceuticals. J Med Chem 2006;49:5408-10. [DOI: 10.1021/jm0606387] [Cited by in Crossref: 47] [Cited by in F6Publishing: 42] [Article Influence: 2.9] [Reference Citation Analysis]
110 Johnson CV, Shelton T, Smith CJ, Ma L, Perry MC, Volkert WA, Hoffman TJ. Evaluation of combined (177)Lu-DOTA-8-AOC-BBN (7-14)NH(2) GRP receptor-targeted radiotherapy and chemotherapy in PC-3 human prostate tumor cell xenografted SCID mice. Cancer Biother Radiopharm 2006;21:155-66. [PMID: 16706636 DOI: 10.1089/cbr.2006.21.155] [Cited by in Crossref: 28] [Cited by in F6Publishing: 24] [Article Influence: 1.8] [Reference Citation Analysis]
111 Koukouraki S, Strauss LG, Georgoulias V, Eisenhut M, Haberkorn U, Dimitrakopoulou-Strauss A. Comparison of the pharmacokinetics of 68Ga-DOTATOC and [18F]FDG in patients with metastatic neuroendocrine tumours scheduled for 90Y-DOTATOC therapy. Eur J Nucl Med Mol Imaging 2006;33:1115-22. [PMID: 16763820 DOI: 10.1007/s00259-006-0110-x] [Cited by in Crossref: 112] [Cited by in F6Publishing: 92] [Article Influence: 7.0] [Reference Citation Analysis]
112 Giblin MF, Sieckman GL, Shelton TD, Hoffman TJ, Forte LR, Volkert WA. In vitro and in vivo evaluation of 177Lu- and 90Y-labeled E. coli heat-stable enterotoxin for specific targeting of uroguanylin receptors on human colon cancers. Nuclear Medicine and Biology 2006;33:481-8. [DOI: 10.1016/j.nucmedbio.2006.01.009] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 1.0] [Reference Citation Analysis]
113 Koukouraki S, Strauss LG, Georgoulias V, Schuhmacher J, Haberkorn U, Karkavitsas N, Dimitrakopoulou-Strauss A. Evaluation of the pharmacokinetics of 68Ga-DOTATOC in patients with metastatic neuroendocrine tumours scheduled for 90Y-DOTATOC therapy. Eur J Nucl Med Mol Imaging 2006;33:460-6. [PMID: 16437218 DOI: 10.1007/s00259-005-0006-1] [Cited by in Crossref: 88] [Cited by in F6Publishing: 81] [Article Influence: 5.5] [Reference Citation Analysis]
114 Maes V, Hultsch C, Kohl S, Bergmann R, Hanke T, Tourwé D. Fluorescein-labeled stable neurotensin derivatives. J Pept Sci 2006;12:505-8. [DOI: 10.1002/psc.757] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
115 Miao Y, Hoffman TJ, Quinn TP. Tumor-targeting properties of 90Y- and 177Lu-labeled alpha-melanocyte stimulating hormone peptide analogues in a murine melanoma model. Nucl Med Biol 2005;32:485-93. [PMID: 15982579 DOI: 10.1016/j.nucmedbio.2005.03.007] [Cited by in Crossref: 39] [Cited by in F6Publishing: 39] [Article Influence: 2.3] [Reference Citation Analysis]
116 Patel HJ, Ramkissoon SH, Patel PS, Rameshwar P. Transformation of breast cells by truncated neurokinin-1 receptor is secondary to activation by preprotachykinin-A peptides. Proc Natl Acad Sci USA. 2005;102:17436-17441. [PMID: 16291810 DOI: 10.1073/pnas.0506351102] [Cited by in Crossref: 48] [Cited by in F6Publishing: 45] [Article Influence: 2.8] [Reference Citation Analysis]
117 Li Y, Si JM, Zhang J, Du J, Wang F, Jia B. Somatostatin receptor subtype 2-mediated scintigraphy and localization using 99mTc-HYNIC-Tyr3-octreotide in human hepatocellular carcinoma-bearing nude mice. World J Gastroenterol 2005; 11(25): 3953-3957 [PMID: 15991301 DOI: 10.3748/wjg.v11.i25.3953] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
118 Virgolini I, Traub-Weidinger T, Decristoforo C. Nuclear medicine in the detection and management of pancreatic islet-cell tumours. Best Pract Res Clin Endocrinol Metab 2005;19:213-27. [PMID: 15763696 DOI: 10.1016/j.beem.2004.09.001] [Cited by in Crossref: 67] [Cited by in F6Publishing: 49] [Article Influence: 3.9] [Reference Citation Analysis]
119 Ferone D, Semino C, Boschetti M, Cascini GL, Minuto F, Lastoria S. Initial Staging of Lymphoma With Octreotide and Other Receptor Imaging Agents. Seminars in Nuclear Medicine 2005;35:176-85. [DOI: 10.1053/j.semnuclmed.2005.03.001] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 1.2] [Reference Citation Analysis]
120 Ertay T, Ünak P, Tasci C, Zihnioğlu F, Durak H. Scintigraphic imaging with 99mTc- exorphin C in rabbits. Applied Radiation and Isotopes 2005;62:883-8. [DOI: 10.1016/j.apradiso.2004.10.016] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
121 Breeman WAP, de Jong M, de Blois E, Bernard BF, Konijnenberg M, Krenning EP. Radiolabelling DOTA-peptides with 68Ga. Eur J Nucl Med Mol Imaging 2005;32:478-85. [DOI: 10.1007/s00259-004-1702-y] [Cited by in Crossref: 198] [Cited by in F6Publishing: 171] [Article Influence: 11.6] [Reference Citation Analysis]
122 Poole RA, Bobba G, Cann MJ, Frias J, Parker D, Peacock RD. Synthesis and characterisation of highly emissive and kinetically stable lanthanide complexes suitable for usage ‘in cellulo’. Org Biomol Chem 2005;3:1013-24. [DOI: 10.1039/b418964g] [Cited by in Crossref: 108] [Cited by in F6Publishing: 101] [Article Influence: 6.4] [Reference Citation Analysis]
123 Eberle AN, Mild G, Froidevaux S. Receptor-Mediated Tumor Targeting with Radiopeptides. Part 1. General Concepts and Methods: Applications to Somatostatin Receptor-Expressing Tumors. Journal of Receptors and Signal Transduction 2004;24:319-455. [DOI: 10.1081/rrs-200040939] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 0.6] [Reference Citation Analysis]
124 Mansi R, Tesauro D, De Capua A, Fattorusso R, Caracò C, Aloj L, Benedetti E, Morelli G. Peptide-chelating agent conjugate for selective targeting of somatostatin receptor type 1: synthesis and characterization. Biopolymers 2004;76:527-34. [PMID: 15526334 DOI: 10.1002/bip.20169] [Reference Citation Analysis]
125 Cui X, Calhorda M, Costa P, Delgado R, Drew M, Félix V. Structure, Characterization, and Metal-Complexation Properties of a New Tetraazamacrocycle Containing Two Phenolic Pendant Arms. HCA 2004;87:2613-28. [DOI: 10.1002/hlca.200490235] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
126 André JP, Geraldes CFGC, Martins JA, Merbach AE, Prata MIM, Santos AC, de Lima JJP, Tóth É. Lanthanide( III ) Complexes of DOTA-Glycoconjugates: A Potential New Class of Lectin-Mediated Medical Imaging Agents. Chemistry - A European Journal 2004;10:5804-16. [DOI: 10.1002/chem.200400187] [Cited by in Crossref: 80] [Cited by in F6Publishing: 72] [Article Influence: 4.4] [Reference Citation Analysis]
127 Van Den Bossche B, Van de Wiele C. Receptor Imaging in Oncology by Means of Nuclear Medicine: Current Status. JCO 2004;22:3593-607. [DOI: 10.1200/jco.2004.10.216] [Cited by in Crossref: 63] [Cited by in F6Publishing: 55] [Article Influence: 3.5] [Reference Citation Analysis]
128 Koglin N, Beck-sickinger AG. Novel modified and radiolabelled neuropeptide Y analogues to study Y-receptor subtypes. Neuropeptides 2004;38:153-61. [DOI: 10.1016/j.npep.2004.04.002] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.4] [Reference Citation Analysis]
129 Landon LA, Deutscher SL. Combinatorial discovery of tumor targeting peptides using phage display. J Cell Biochem. 2003;90:509-517. [PMID: 14523985 DOI: 10.1002/jcb.10634] [Cited by in Crossref: 63] [Cited by in F6Publishing: 61] [Article Influence: 3.5] [Reference Citation Analysis]
130 Carlsson J, Nordgren H, Sjöström J, Wester K, Villman K, Bengtsson NO, Ostenstad B, Lundqvist H, Blomqvist C. HER2 expression in breast cancer primary tumours and corresponding metastases. Original data and literature review. Br J Cancer 2004;90:2344-8. [PMID: 15150568 DOI: 10.1038/sj.bjc.6601881] [Cited by in Crossref: 159] [Cited by in F6Publishing: 145] [Article Influence: 8.8] [Reference Citation Analysis]
131 Kennedy MD, Jallad KN, Thompson DH, Ben-Amotz D, Low PS. Optical imaging of metastatic tumors using a folate-targeted fluorescent probe. J Biomed Opt 2003;8:636-41. [PMID: 14563201 DOI: 10.1117/1.1609453] [Cited by in Crossref: 62] [Cited by in F6Publishing: 58] [Article Influence: 3.4] [Reference Citation Analysis]
132 Grötzinger C, Wiedenmann B. Somatostatin receptor targeting for tumor imaging and therapy. Ann N Y Acad Sci 2004;1014:258-64. [PMID: 15153442 DOI: 10.1196/annals.1294.028] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
133 Wester H, Schottelius M, Poethko T, Bruus-jensen K, Schwaiger M. Radiolabeled Carbohydrated Somatostatin Analogs: A Review of the Current Status. Cancer Biotherapy and Radiopharmaceuticals 2004;19:231-44. [DOI: 10.1089/108497804323072011] [Cited by in Crossref: 28] [Cited by in F6Publishing: 24] [Article Influence: 1.6] [Reference Citation Analysis]
134 Okarvi S. Peptide-based radiopharmaceuticals: Future tools for diagnostic imaging of cancers and other diseases. Med Res Rev 2004;24:357-97. [DOI: 10.1002/med.20002] [Cited by in Crossref: 165] [Cited by in F6Publishing: 152] [Article Influence: 9.2] [Reference Citation Analysis]
135 Häfeli UO, Yu J, Farudi F, Li Y, Tapolsky G. Radiolabeling of magnetic targeted carriers (MTC) with indium-111. Nuclear Medicine and Biology 2003;30:761-9. [DOI: 10.1016/s0969-8051(03)00077-5] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
136 Wild D, Schmitt JS, Ginj M, Mäcke HR, Bernard BF, Krenning E, De Jong M, Wenger S, Reubi JC. DOTA-NOC, a high-affinity ligand of somatostatin receptor subtypes 2, 3 and 5 for labelling with various radiometals. Eur J Nucl Med Mol Imaging 2003;30:1338-47. [PMID: 12937948 DOI: 10.1007/s00259-003-1255-5] [Cited by in Crossref: 212] [Cited by in F6Publishing: 192] [Article Influence: 11.2] [Reference Citation Analysis]
137 Ou XH, Kuang AR, Peng X, Zhong YG. Study on the possibility of insulin as a carrier of IUdR for hepatocellular carcinoma-targeted therapy. World J Gastroenterol 2003; 9(8): 1675-1678 [PMID: 12918099 DOI: 10.3748/wjg.v9.i8.1675] [Reference Citation Analysis]
138 Paganelli G, Bodei L, Handkiewicz Junak D, Rocca P, Papi S, Lopera Sierra M, Gatti M, Chinol M, Bartolomei M, Fiorenza M, Grana C. 90Y-DOTA-D-Phe1-Try3-octreotide in therapy of neuroendocrine malignancies. Biopolymers 2002;66:393-8. [PMID: 12658726 DOI: 10.1002/bip.10349] [Cited by in Crossref: 71] [Cited by in F6Publishing: 59] [Article Influence: 3.7] [Reference Citation Analysis]
139 Carlsson J, Kullberg EB, Capala J, Sjöberg S, Edwards K, Gedda L. Ligand liposomes and boron neutron capture therapy. J Neuro-Oncol 2003;62:47-59. [DOI: 10.1007/bf02699933] [Cited by in Crossref: 16] [Cited by in F6Publishing: 19] [Article Influence: 0.8] [Reference Citation Analysis]
140 Carlsson J, Forssell Aronsson E, Hietala S, Stigbrand T, Tennvall J. Tumour therapy with radionuclides: assessment of progress and problems. Radiotherapy and Oncology 2003;66:107-17. [DOI: 10.1016/s0167-8140(02)00374-2] [Cited by in Crossref: 77] [Cited by in F6Publishing: 62] [Article Influence: 4.1] [Reference Citation Analysis]
141 Janin YL. Peptides with anticancer use or potential. Amino Acids 2003;25:1-40. [DOI: 10.1007/s00726-002-0349-x] [Cited by in Crossref: 45] [Cited by in F6Publishing: 39] [Article Influence: 2.4] [Reference Citation Analysis]
142 Morelli G, De Luca S, Tesauro D, Saviano M, Pedone C, Dolmella A, Visentin R, Mazzi U. CCK8 peptide derivatized with diphenylphosphine for rhenium labelling: synthesis and molecular mechanics calculations. J Pept Sci 2002;8:373-81. [PMID: 12148786 DOI: 10.1002/psc.400] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 0.5] [Reference Citation Analysis]
143 Evans JW, Peters AM. Gamma camera imaging in malignancy. Eur J Cancer 2002;38:2157-72. [PMID: 12387841 DOI: 10.1016/s0959-8049(02)00412-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
144 Unak P. Targeted tumor radiotherapy. Braz arch biol technol 2002;45:97-110. [DOI: 10.1590/s1516-89132002000500014] [Cited by in Crossref: 32] [Cited by in F6Publishing: 27] [Article Influence: 1.6] [Reference Citation Analysis]
145 Bhargava S, Licha K, Knaute T, Ebert B, Becker A, Grötzinger C, Hessenius C, Wiedenmann B, Schneider-mergener J, Volkmer-engert R. A complete substitutional analysis of VIP for better tumor imaging properties: COMPLETE SUBSTITUTIONAL ANALYSIS of VIP. J Mol Recognit 2002;15:145-53. [DOI: 10.1002/jmr.565] [Cited by in Crossref: 41] [Cited by in F6Publishing: 30] [Article Influence: 2.1] [Reference Citation Analysis]
146 Chinol M, Bodei L, Cremonesi M, Paganelli G. Receptor-mediated radiotherapy with Y-DOTA-DPhe-Tyr-octreotide: the experience of the European Institute of Oncology Group. Semin Nucl Med 2002;32:141-7. [PMID: 11965609 DOI: 10.1053/snuc.2002.31563] [Cited by in Crossref: 90] [Cited by in F6Publishing: 75] [Article Influence: 4.5] [Reference Citation Analysis]
147 Warner RR, O'dorisio TM. Radiolabeled peptides in diagnosis and tumor imaging: Clinical overview. Seminars in Nuclear Medicine 2002;32:79-83. [DOI: 10.1053/snuc.2002.31020] [Cited by in Crossref: 46] [Cited by in F6Publishing: 36] [Article Influence: 2.3] [Reference Citation Analysis]
148 Ferone D, Hofland LJ, Colao A, Lamberts SW, van Hagen PM. Neuroendocrine aspects of immunolymphoproliferative diseases. Ann Oncol 2001;12 Suppl 2:S125-30. [PMID: 11762338 DOI: 10.1093/annonc/12.suppl_2.s125] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.3] [Reference Citation Analysis]
149 Lou C, Chen ZN, Bian HJ, Li J, Zhou SB. Pharmacokinetics of radioimmunotherapeutic agent of direct labeling mAb 188Re-HAb18. World J Gastroenterol 2002; 8(1): 69-73 [PMID: 11833074 DOI: 10.3748/wjg.v8.i1.69] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 7] [Article Influence: 0.3] [Reference Citation Analysis]
150 Ugur Ö, Kothari PJ, Finn RD, Zanzonico P, Ruan S, Guenther I, Maecke HR, Larson SM. Ga-66 labeled somatostatin analogue DOTA-DPhe 1 -Tyr 3 -octreotide as a potential agent for positron emission tomography imaging and receptor mediated internal radiotherapy of somatostatin receptor positive tumors. Nuclear Medicine and Biology 2002;29:147-57. [DOI: 10.1016/s0969-8051(01)00290-6] [Cited by in Crossref: 68] [Cited by in F6Publishing: 57] [Article Influence: 3.4] [Reference Citation Analysis]
151 Bergmann R, Scheunemann M, Heichert C, Mäding P, Wittrisch H, Kretzschmar M, Rodig H, Tourwé D, Iterbeke K, Chavatte K, Zips D, Reubi JC, Johannsen B. Biodistribution and catabolism of 18F-labeled neurotensin(8–13) analogs. Nuclear Medicine and Biology 2002;29:61-72. [DOI: 10.1016/s0969-8051(01)00284-0] [Cited by in Crossref: 69] [Cited by in F6Publishing: 62] [Article Influence: 3.5] [Reference Citation Analysis]
152 Woods M, Kovacs Z, Sherry A. Targeted Complexes of Lanthanide(III) Ions as Therapeutic and Diagnostic Pharmaceuticals. Journal of Supramolecular Chemistry 2002;2:1-15. [DOI: 10.1016/s1472-7862(02)00072-2] [Cited by in Crossref: 64] [Cited by in F6Publishing: 51] [Article Influence: 3.2] [Reference Citation Analysis]